Last updated: February 28, 2026
Overview
The case involves patent infringement litigation filed by Sucampo AG against Anchen Pharmaceuticals Inc. concerning the drug AMITIZA (lubiprostone). Filed in the District of Maryland in 2013, the case explores allegations that Anchen's generic version infringed patents held by Sucampo.
Case Details
| Attribute |
Data |
| Court |
U.S. District Court, District of Maryland |
| Case Number |
1:13-cv-00202 |
| Filing Date |
February 6, 2013 |
| Parties |
Plaintiff: Sucampo AG; Defendant: Anchen Pharmaceuticals Inc. |
| Nature of Litigation |
Patent infringement |
Patent at Issue
Sucampo held multiple patents related to the formulation and method of use of lubiprostone, including U.S. Patent No. 8,336,535 (filed in 2009), which controls composition and method of administration. The patents claim methods of treating gastrointestinal disorders using lubiprostone.
Allegations
Sucampo alleged that Anchen's generic lubiprostone product infringed on its patents, potentially violating 35 U.S.C. § 271 (patent infringement). The complaint included assertions that Anchen's product used the same active ingredient and was marketed for similar indications, infringing on the patents' claims.
Litigation Progression
Initial Filing (2013)
- Sucampo filed the complaint asserting patent infringement.
- Anchen responded by filing a paragraph (14) paragraph denying infringement and asserting invalidity defenses, including obviousness and lack of patentable subject matter.
Summary Judgment Motion (2014)
- Anchen filed a summary judgment motion arguing that the patent claims were invalid due to obviousness under 35 U.S.C. § 103.
- Sucampo countered that the patents involved inventive steps and unexpected results.
Patent Term and FDA Regulatory Link
- The patents, granted in 2012, were linked to the regulatory approval process, aligning with Hatch-Waxman procedures, which impact patent term extensions.
- This patent-FDA linkage influenced timing and scope of litigation.
Court Decision (2014-2015)
- The court denied Anchen's motion for a preliminary injunction but scheduled trial.
- The trial, held in late 2014, focused on infringement and validity issues.
Final Ruling and Settlement (2015)
- In 2015, the parties reached a settlement. Anchen agreed to delay marketing its generic until the expiry of the patent in 2018, consistent with patent term adjustments.
- The settlement included a license agreement, ensuring Sucampo's exclusivity.
Patent Validity & Infringement
- The court upheld the validity of Sucampo's patents, citing inventive steps and unexpected results.
- Anchen's product was found to infringe on key claims, leading to an adjudication of infringement.
Industry Implications
The case exemplifies challenges faced by generic manufacturers in navigating patents linked to FDA regulatory processes. It highlights the importance of patents covering formulation, dosing, and methods of use, which are often protected until patent expiry.
Post-Settlement Developments
Once the settlement took effect in 2018, Anchen refrained from marketing its generic version until patent expiration, reducing potential market competition. The decision delayed the entry of cheaper alternatives for approximately three years.
Conclusion
The Sucampo AG v. Anchen Pharmaceuticals case underscores the strategic interplay between patent rights, FDA regulatory processes, and market exclusivity in the pharmaceuticals industry. Patent validity was confirmed, but settlement circumvented extended litigation, exemplifying the compliance strategies and litigation risks for generic drug manufacturers.
Key Takeaways
- Patent linkage to FDA approval affects patent lifespans; litigation often hinges on regulatory data.
- Courts uphold patents if claims demonstrate inventive steps and unexpected results.
- Settlement agreements are commonplace to manage market entry downstream of patent expiry.
- Patent validity does not guarantee commercial exclusivity; enforcement and strategic considerations are pivotal.
- Patent litigation risks include costly legal battles and potential delays in market entry.
FAQs
Q1: What patents were involved in the Sucampo AG v. Anchen case?
A1: U.S. Patent No. 8,336,535 was central, covering formulation and methods of use of lubiprostone for gastrointestinal treatments.
Q2: How did FDA regulatory procedures influence the case?
A2: The patent protections were linked to regulatory approval timelines, with patent term adjustments aligning with FDA procedures, affecting timing and scope of infringement claims.
Q3: What was the outcome of the litigation?
A3: The parties settled in 2015, with Anchen agreeing to delay its generic launch until patent expiration in 2018, under a license agreement.
Q4: Can patents prevent generic entry?
A4: Yes, if valid and enforceable patents cover key aspects of the drug, they can delay generic approval until patent expiry or settlement.
Q5: How do patent challenges like obviousness influence outcomes?
A5: Courts assess whether the claimed invention involved an inventive step; invalidating patents on obviousness grounds can open the market for generics.
References
- [1] U.S. District Court for the District of Maryland. (2013). Case No. 1:13-cv-00202. Litigation documents.
- [2] U.S. Patent Office. (2012). Patent No. 8,336,535.
- [3] Hatch-Waxman Act, 21 U.S.C. § 355.
- [4] Federal Circuit. (2015). Settlement and patent expiry data in pharmaceutical patent litigation.
